Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-)

Journal of the International Association of Physicians in AIDS Care

Volumn 11, Issue 3, 2012, Pages 192-197

  Antoniou, Tony ^a,b   Smith, Graham ^a,c   Su, Desheng ^d   Raboud, Janet M ^a,d   Lee, Derek ^c   Kovacs, Colin ^a,c   Brunetta, Jason ^a,c   Fletcher, David ^a,c   Crouzat, Fred ^a,c   Loutfy, Mona ^a,c,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c MAPLE LEAF MEDICAL CLINIC   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

anti HIV agents; antiretroviral therapy; highly active; maraviroc; raltegravir; retrospective studies

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CREATINE KINASE; CREATININE; LOW DENSITY LIPOPROTEIN; MARAVIROC; RALTEGRAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RETROSPECTIVE STUDIES; TRIAZOLES; VIRAL LOAD;

EID: 84860740605     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109711424967     Document Type: Article

References (15)

1. Dorr P, Westby M, Dobbs S. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-HIV type 1 activity. Antimicrob Agents Chemother. 2005 ; 49 ((11 )). 4721-4732
2. Baba M, Nishimura O, Kanzaki N. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A. 1999 ; 96 ((10 )). 5698-5703
3. Castonguay L, Wengg Y, Adolfsen W. Binding of 2-aryl-4(piperidin-1yl) butanmines and 1, 3, 4-trisubstitued pyrrolidines to human CCR5: a molecular modelling-guide mutagenesis study of the binding pocket. Biochemistry. 2003 ; 42 ((6 )). 1544-1550
4. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008 ; 359 (14). 1429-1441
5. Fätkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med. 2008 ; 359 ((14 )). 1442-1455
6. Hardy WD, Gulick R, Mayer HB, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. Efficacy and safety of maraviroc in treatment-experienced patients infected with R5 HIV-I: 96-week combined analysis of the MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010 ; 55: 558-564
7. Asmuth DM, Goodrich J, Cooper DA, et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010 ; 54: 394-397
8. Funderburg N, Kalinowska M, Eason J, et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell risk in HIV-infected patients. PLoS One. 2010 ; 5 (10). e13188
9. Baroncelli S, Villani P, Weimer L, et al. Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration. Ann Pharmacother. 2010 ; 44 (5). 838-843
10. Table of Grading Severity of Adult Adverse Experiences. Division of AIDS. National Institute of Allergy and Infectious Diseases: Rockville, MD ; 2004:
11. Saag M, Goodrich J, Fätkenheuer G, et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis. 2009 ; 199 ((11 )). 1638-1647
12. Wilkin T, Ribaudo H, Gulick R.. The relationship of CCR5 inhibitors to CD4 cell count changes: a meta-analysis of recent clinical trials. In: Abstracts and Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections ; 2008 ; 2008..
13. Pichenot M, Deuffic-Burban S, Cuzin L, Yazdanpanah Y.. CCR5 Inhibitors and CD4 Cell Count Change in Treatment Experienced Patients. In: Abstracts and Proceedings of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) ; ;..
14. Stepanyuk O, Chiang TS, Dever LL, et al. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery. AIDS. 2009 ; 23 (14). 1911-1913
15. Wilkin T, Lalama C, Tenoria A, et al. Maraviroc intensification for suboptimal CD4+ cell response despite sustained virologic suppression: ACTG 5256. In: Abstracts and Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections ; 2010 ; 2010..